We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Sign in
Join now
David Lieberman

David Lieberman MD

Professor of Medicine; Chief, Division of Gastroenterology and Hepatology, Oregon Health and Science University (OHSU), Portland, Oregon

David Lieberman MD, is Professor of Medicine and Chief of the Division of Gastroenterology and Hepatology at Oregon Health and Science University (OHSU) in Portland, Oregon and the Portland VA Medical Center. Dr. Lieberman is internationally recognized as an expert on colon cancer screening, with major research publications in New England Journal of Medicine, JAMA, Annals of Internal Medicine and Gastroenterology.  Dr. Lieberman was the Chairman of the Multi-Society Task Force on Colorectal Cancer (2006-2012), and authored colon cancer screening guidelines in 2008 and polyp surveillance guideline in 2012 as well as colonoscopy quality indicators in 2007. He is the Director of the Clinical Outcomes Research Initiative (CORI), supported by NIH since 1999, which studies quality of endoscopy.  Dr. Lieberman was Associate Editor of Gastroenterology (2011-2013) and is a member of the AGA Board (2012-2015).  

Recent Contributions to PracticeUpdate:

  1. Fecal Microbial DNA Markers Serve for Screening Colorectal Neoplasm in Asymptomatic Individuals
  2. Influence of Varying Quantitative Fecal Immunochemical Test Positivity Thresholds on Colorectal Cancer Detection
  3. Determining Risk of Colorectal Cancer and Starting Age of Screening Based on Lifestyle, Environmental, and Genetic Factors
  4. Germline Genetic Features of Young Patients With Colorectal Cancer
  5. Modifiable Risk Factors for Sessile Serrated Polyps, Conventional Adenomas, and Hyperplastic Polyps
  6. Correlation of Distal Polyps With Proximal Advanced Serrated Lesions
  7. Incidence of Colonic Neoplasia in Patients With Serrated Polyposis Syndrome Who Undergo Annual Endoscopic Surveillance

Most Read This Week

Recently Updated